Search

EHA-SfPM Precision Medicine Meeting

EHA and SfPM (Society for Functional Precision Medicine) are proud to present the first joint meeting on Precision Medicine.

Read more

How to apply

The CRTH 2025 call for applications are open. Apply now

Timelines
Application CRTH 2025
Deadline: August 30, 2024 (12:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Read more

Great new opportunity for the YoungEHA community!

Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee

The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…

Read more

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Read more

EHA-EBMT 2nd European CAR T Cell Meeting

Dates:             January 30 – February 1, 2020
Location:        Sitges (Barcelona), Spain
Chairs:            H Einsele, C Chabannon

The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of the EHA

During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more